Abstract Cell adhesion to the extracellular matrix (ECM) is necessary for development of the mammary gland, and to maintain the normal architecture and function of the gland. Cells adhere to the ECM via the integrin family of transmembrane receptors, which signal to control mammaryspecific gene expression and regulate cell proliferation and survival. During tumor formation, the ECM is extensively remodeled and signaling through integrins is altered such that cells become proliferative and invasive. A key regulator of whether integrin-mediated adhesion will promote tumor suppression or tumor formation is the stiffness of the stromal ECM. The normal mammary gland is typically surrounded by a loose collagenous stroma. An increase in the deposition of collagen and other stromal components is associated with mammographic density, which is one of the greatest risk factors for developing breast carcinoma. Several groups have demonstrated that increased stromal ECM density results in a matrix that is stiffer. Cells sense the stiffness of their surrounding ECM by Rho-mediated contraction of the actin-myosin cytoskeleton. If the surrounding ECM is stiffer than the cell's ability to contract it, then the tensile forces that result are able to drive the clustering of integrins and assemble adhesion signaling complexes. The result is subsequent activation of signaling pathways including FAK, ERK, and PI3K that drive cell proliferation and survival. In contrast, focal complexes are not formed in a compliant matrix, and activation of FAK and pERK is diminished, resulting in control of proliferation. Signaling from FAK moreover regulates p53 and miR-200 members, which control apoptosis and epithelial phenotype, such that a compliant matrix is predicted to promote normal mammary gland architecture and suppress tumor formation.
disruption of normal control mechanisms and lead to a loss of normal tissue architecture. Of relevance to this chapter, the ECM impinges upon the regulation of each of these hallmark processes, and therefore is poised to be a regulator of whether cells exhibit a normal or a transformed phenotype.
The normal architecture of the mammary gland is comprised of an epithelium organized into a branching ductal tree. This branching ductal tree is surrounded by a loose stromal connective tissue deposited by stromal fibroblasts and comprised predominantly of fibrillar collagens, fibronectin, and proteoglycans. The mammary gland and its stroma exists in the context of adipose tissue, the mammary fat pad. The adipose tissue contributes much to regulating the metabolism and hormonal milieu of the gland, but will not be further discussed here (for a review, see [2] ). The mammary gland is unique in that much of its differentiation and formation of an extensive ductal tree occurs only in response to a set of hormonal cues at puberty, pregnancy, and during lactation. The mammary epithelium is organized into two layers: the luminal epithelial cells that make milk proteins, and the highly contractile basal, or myo-epithelial, cells surrounding the luminal cells. The myoepithelial cells contact the basal lamina, and regulate the function and polarity of the apical cells. Much evidence supports the notion that adhesion to the basal lamina helps to establish cellular polarity [3] [4] [5] [6] . Proteins comprising the basal lamina include collagen IV, laminin-1 and laminin-5 (epiligrin), entactin and proteoglycans [7, 8] .
Attachment of individual cells to the basal lamina occurs through integrins, a family of heterodimeric receptors for the ECM. Several alpha and beta subunits exist, and combine in different pairings to provide both ligand and signaling specificity (reviewed in [9] ). In particular, adhesion to the basal lamina occurs through the α6β4 integrin, which is uniquely found at hemidesmosomes. Adhesion to the basal lamina regulates apical secretion, mammary-specific gene expression, and control of proliferation and apoptosis [10, 11] . Tissue structure is further maintained by cell-cell attachments through E-cadherin, and evidence is emerging that suggests that there is crosstalk between E-cadherin and integrins [12] .
Upon transformation, it is well established that cell-cell and cell-matrix attachments are lost or altered, with a resulting loss in tissue architecture. Tumor formation is moreover marked by an increase in cell proliferation, changes in gene expression, and upregulation of several signaling pathways. At the tissue level, tumor progression is accompanied by disruption and proteolysis of the basement membrane, and an increase in the deposition of the stromal ECM. It is the purpose of this chapter to consider the ways in which the ECM works to hold cells in the differentiated state, and thereby act as a tumor suppressor. In order to understand this process fully, we will also consider mechanisms by which altered ECM architecture affects tumor formation or progression.
Regulation of the ECM During Normal Mammary Development
The mammary gland is unique in that the majority of ductal development occurs in response to hormonal stimuli at puberty and subsequent alveolar development with pregnancy, with full terminal differentiation occurring only if lactation ensues. Each developmental state has a unique ECM protein content, which regulates mammary gland differentiation and gene expression [13] [14] [15] [16] . The changes in gene expression include not only laminins, but also fibrillar collagens type I, III, and V, bead-filament collagen VI, collagen IX, basal lamina collagen IV and collagen-associated proteins known to effect cross linking such as elastin, fibrillin 1, decorin, lumican, and biglycan [17] . Loss of lobuloalveolar development occurs when FN is knocked-out in the mammary epithelium and is linked to diminished integrin signaling events [18] , suggesting an intriguing autocrine regulation of morphogenesis by local epithelial secretion of fibronectin.
A role for fibrillar collagen in regulating development of the ductal mammary tree is suggested by findings that collagen deposition occurs along the sides of developing ducts, where epithelial cell proliferation is minimal [19] . In contrast, relatively little collagen is present at the terminal end buds (TEBs), which are the mitotically active and motile structures that drive ductal elongation and penetration through the fat pad. Application of exogenous TGF-β at the tip of the growing ductal tree inhibits ductal growth and coordinately results in the deposition of thick fibrillar collagen around the TEBs [20] .
The control of not only ECM deposition, but also degradation, is an important regulator of the formation of the ductal tree, as appropriate stromelysin-1, -3, gelatinase, and matrilysin are necessary for branching morphogenesis to occur [21] [22] [23] [24] . These findings support the idea that the growth of the mammary ductal tree is a process of controlled proliferation and invasion at the TEB. This process needs to be highly regulated, as inappropriate degradation of the basal lamina components by stromelysin/MMP3 causes disruption of cellular polarization and promotes tumor cell invasion [25] . The effect of degrading the basal lamina is so profound that induced expression of stromelysin-1 in mouse mammary gland promotes the formation of de novo invasive tumors [26] , demonstrating that an intact basal lamina suppresses tumor formation.
The finding that proteases such as stromelysin-1 regulate normal branching morphogenesis during development as well as tumor formation demonstrates the delicate balance that must be struck between an intact ECM composed of the appropriate proteins, and the degradation of the ECM. In general, in normal mammary tissue, degradation of ECM and protease activity corresponds to tissue remodeling: invasion of the ductal tree into the mammary fat pad and branching morphogenesis during development, and involution following lactation. The fact that similar degradation accompanies tumor formation suggests this is the co-opting of the developmental program by breast carcinoma cells, which also remodel and invade the breast stroma and fat pad.
Involution and Insights for Tumor Suppression
The mammary gland is further unique, in that it undergoes extensive remodeling upon weaning, when the gland involutes. Involution is accompanied by extensive remodeling of the ECM and degradation of laminins, entactin, and basal lamina collagen IV [27, 28] (see Fig. 1 ). As the normal ECM is degraded, production of milk proteins is inhibited [29] . Moreover, the increase in other proteins likely contributes to this effect, as inhibition of milk protein expression has been linked to an increase in the ECM protein, Tenascin-C, during involution [14, 30] , and increased level of fibrillar collagen become deposited [31] .
It has recently been demonstrated that the involuting mammary stroma promotes breast carcinoma de-differentiation and metastasis [32] . This suggests that the extensive remodeling that occurs in the involuting stroma may destroy or override some tumor-suppressive property of the normal mammary gland ECM. Consistent with this idea, during tumor formation and progression, there are several changes to the mammary stroma that mimic the changes observed during involution. One similarity is the degradation of the basal lamina that accompanies tumor cell invasion, which mimics the proteolysis observed in involution [32] . In addition to the loss of the tumor suppressive roles of the basal lamina, there is evidence that the degraded ECM components can have unique function. For example, laminin-5 is a major component of the mammary basal lamina, and its cleavage by MMP-2 exposes a cryptic site in laminin-5 that promotes cell migration and invasion [33] [34] [35] . For example, one of the peptides released by laminin degradation can bind and stimulate cells through the EGFR [35] . A second way that tumor progression parallels involution is in the increased deposition of an altered ECM. This process, termed desmoplasia, is characterized by the increased deposition of a fibrotic stromal matrix. In addition to collagen I, there is a dramatic increase in collagen V deposition into desmoplastic stroma [36] , which is mechanically significant as collagen V changes the structure of collagen I fibrils [37] [38] [39] . Again, this is similar to the increases in collagens that accompany invasion of the branching ductal tree into the mammary fat pad [40] and the increase in collagens that accompany involution [14] .
Integrins are Involved in Both Tumor Suppression and Tumor Promotion
Cells attach to the ECM through several receptors, the dominant members of which are the integrins. Integrins play important roles in promoting the normal phenotype of cells, and are necessary for mammary epithelial differentiation both in vitro and in vivo [41] [42] [43] [44] . Adhesion to the basement membrane through β1 integrin activates Rac, and this provides a necessary signal that regulates lactational differentiation in response to prolactin [45] . Indeed, loss of certain integrin subunits, including α6 and α2, accompanies mammary tumor progression [46, 47] , consistent with a model in which α2β1 and α6β4 integrins are tumor-suppressive.
The α6β4 integrin, found at the basal surface of polarized epithelial cells in the hemi-desmosomes, is a necessary regulator of normal mammary epithelial polarization and mammary differentiation [48, 49] . The α6β4 integrin activates Rac, and its effector PAK1, to activate NFkB and promote survival [50] . The activation of Rac1 is not only regulated by polarity, but contributes to polarity as it drives basal assembly of laminin in MDCK cells [51] . When β4 integrin is blocked, not only is the normal architecture of the mammary gland lost, but the cells become sensitive to apoptotic events, demonstrating that the normal function of α6β4 integrin includes cell survival [52] .
Several lines of evidence support the view that integrins are both important regulators of mammary phenotype, and are necessary for tumor formation and progression. Integrin activation of Rac promotes cell cycle progression by regulating G1 via cyclin D1, CDK4 and CDK6 [53] , which continues without control when cells are transformed. The tumor-promoting role of some members of the β1 integrin family is demonstrated by the finding that the malignant phenotype can be reverted using β1 integrin blocking antibodies both within 3D cultures and in vivo [49] . Knock-out of β1 integrin in mice suppresses the formation of mammary tumors [54] , but also diminishes branching complexity during mammary gland development [44, 55] . Moreover, the α6β4 integrin can be co-opted in mammary tumor cells to activate PI3-Kinase and promote migration and invasion [48] .
The dual role of integrins suggests that their regulation is key to whether the ECM plays a role as a tumor suppressor or a tumor promoter. This regulation can be due to the specific composition of the ECM. For example, in normal MECs, adhesion to collagen via α2β1 integrin causes an increase in Rac activation, while adhesion to laminin via α6β4 integrin inhibits activation of Rac [56] . The regulation of signaling pathways by specific integrins is cell-type specific, as adhesion of Human Umbilical Vein endothelial cells (HUVECs) to fibronectin via the α5β1 integrin activates Rac to promote cell cycle progression in response to growth factors, while adhesion to laminin via the α2β1 integrin does not activate Rac nor lead to cell cycle progression [53] .
In normal mammary epithelial cells, cell proliferation is also controlled by cell-cell attachments through E-cadherin [57] , suggesting that a coordinated control of cell proliferation in polarized epithelial cells occurs by adhesion to the basement membrane as well as through cell-cell contacts. The loss of E-cadherin mediated cell-cell adhesions during tumorigenesis would release cells from growth control, and allow uncontrolled proliferation.
Regulation of integrin function also occurs through syndecans, which are trans-membrane proteoglycans that can bind to several ECM proteins including laminin and collagens [58] . Syndecan-1 (Sdc-1) is abundant on mammary epithelia, and is often diminished in human breast cancer patients [59] , suggesting it may play a tumor suppressive function. The cytoplasmic domain of Sdc-1 has signaling capability through both tyrosine kinase and PKC pathways [60] . Recently, it was shown that Sdc-1 enhances signaling through the avβ1 integrin in mammary epithelial cells [61, 62] , and thus it is poised as a molecule that can direct the outcome of integrin-signaling events. The role of Sdc-1 is complex, however, as it has also been reported that Sdc-1 loss is associated with a decrease in mammary carcinogenesis in rodent models [63] . Moreover, Wnt-induced tumor formation is suppressed in mice in which syndecan-1 (Sdc-1) has been knocked out [64] . Evidence is accumulating that suggests that loss of Sdc-1 affects the stem cell niche [65, 66] .
Mechanical Considerations in Tumor Formation
Not only does the ECM serve an important role as a biochemical ligand for integrins and proteoglycans, recently it has become clear that the stiffness and topography of the ECM surrounding cells also regulates integrin signaling and cell phenotype. The stiffness of the ECM is affected by its composition and organization. An increase in the deposition of the ECM is one way that increased stiffness occurs [67, 68] . Increased deposition of stromal matrix, predominantly collagen, is associated with mammographic density, and is linked to a 4-6 fold increase in development of breast carcinoma [ [69] , [70] ]. Moreover, carcinomas largely arise in the dense regions of the breast, suggesting an important link between density and tumor formation [71] . A more causal link is demonstrated in the finding that a rodent model containing increased collagen deposition, due to altered collagen degradation, exhibits an increase in both mammary tumor formation and progression to metastasis [72] . Moreover, the stiffness of the ECM is likely a "feed forward" mechanism, as the formation of a tumor results in a region that is locally stiffer [67, 73] , and deposition of additional stromal collagen accompanies tumor progression [74] .
In addition to an increase in the amount of collagen, surrounding tumors the structure and organization of the collagen is altered. Collagen fibrils are cross-linked by lysyl oxidase, which is increased in the stroma surrounding tumor [75, 76] . This increased cross-linking makes the stroma stiffer [77] . Moreover, collagen near tumors is reorganized from a loose connective tissue into tracks of parallel and perpendicular fibers, which promote the invasiveness of tumor cells [74, 78, 79] . In patients, the formation of tracts of aligned collagen is associated with poor outcome [80] . In contrast, in normal mammary gland, collagen fibers are less organized [74, 79] , suggesting that a randomly organized, compliant stroma is tumor suppressive.
Mechanisms are emerging by which an aligned stroma is created. While Sdc-1 is lost from human breast carcinoma cells, Sdc-1 levels increase in the stroma and on fibroblasts of mammary carcinomas [59] . Carcinoma-associated fibroblasts have increased Sdc-1 levels and secrete and organize an aligned fibronectin and collagen matrix [79] . Moreover, when normal mammary fibroblasts, which have low Sdc-1 levels, are transfected with Sdc-1, they acquire the ability to secrete an aligned matrix instead of the randomly organized matrix they normally secrete [79] .
Recently, it was demonstrated that caveolin-1 in stromal fibroblasts contributes to the creation of an aligned matrix. Loss of caveolin-1 in stromal fibroblasts results in a tumorassociated stroma that is not organized into perpendicular tracks of collagen fibers, and that does not promote tumor progression [81] . Moreover, the non-aligned tumor associated stroma in the caveolin deficient stroma is more compliant, while the aligned stroma from the wild-type host is stiffer [81] . Consistent with a role for celluluar contractility in creating an aligned stroma, caveolin-deficient fibroblasts have a diminished ability to contract a collagen matrix and to activate Rho [81] . Thus, all these findings support the notion that a compliant matrix is one with more disorganized fibers, and that this is tumor-suppressive compared to a stiffer ECM.
Rho GTPase Regulates Integrins in Response to Matrix Stiffness
The deposition of additional ECM, and its cross-linking and alignment creates an environment that is stiffer surrounding tumors [67, 68, 81] . One important way that mammary epithelial cells respond to matrix stiffness is through Rhomediated contractility. Rho activates contractility through its effector, Rho Kinase (ROCK), leading to subsequent phosphorylation of the regulatory chain of myosin (MLC) and myosin-actin mediated contraction [82] . In vitro models demonstrate that within a stiff matrix, cellular contractility is insufficient to contract the ECM [67, 68, 83] . The hypothesis, although not proven, is that this results in isometric tension within the cell as it "holds" contraction against the matrix. Consistent with this hypothesis, cells within a stiff environment have a more extensively polymerized actin cytoskeleton [67, 68, 83] .
An outcome of Rho-mediated contractility when cells are on rigid 2D surfaces is the assembly of integrin-based focal adhesions [84] . Integrin assembly into focal adhesions is also driven by force applied to the integrin from the outside of the cell [85] . In 3D, we propose that force on the integrins is generated by Rho-mediated contractility pulling against the matrix, and thus the formation of 3D focal adhesions occurs if matrix stiffness is increased [67, 68, 83] . Within a stiffer matrix, larger integrin-containing 3-D focal adhesions are formed than in a more compliant matrix, which results in an increase in associated integrinmediated signaling events including activation of FAK, Src, small GTPases, ERK, and PI3K [67, 68, 83, 86] . These pathways are linked to an increase in cell proliferation and survival in stiff matrices, whereas a control of proliferation is observed in compliant matrices [67, 68, 83] .
Thus, the picture that emerges is that in dense breast tissue and in the stroma of a tumor, which are stiffer, we expect that Rho-mediated contractility will activate integrin-mediated pathways and promote cell proliferation and survival (See Fig. 2 ). This hypothesis is supported by recent findings in skin carcinoma models demonstrating that ROCK activation indeed leads to increased stiffness, increased collagen deposition, and a subsequent increase in tumor growth and progression [73] . Whether this process is able to actually initiate a tumor or serves to potentiate the role of oncogenes in tumorigenesis and progression remains to be determined.
In contrast, within a compliant matrix, evidence suggests that cellular proliferation is attenuated [67, 68, 83] . Instead, based on in vitro work, we propose that Rho-mediated contractility results in local matrix contraction, a rounding of cell shape, and a fundamentally different signaling outcome (Fig. 2) . Thus, when the tissue does not exhibit increased density or stiffness, integrin signaling would be expected to be appropriately regulated, and thus contribute to the normal growth and differentiation of the mammary gland. While much is known about signaling pathways activated in the stiff condition, relatively little is known about how a compliant matrix signals to cells to control growth, and maintain a differentiated state. The prediction is that appropriate adhesion to the basal lamina via integrins is a key aspect, but only under conditions of appropriate compliance.
Rho itself is regulated by matrix stiffness, such that it is activated to the GTP-bound form in a stiff matrix, and inactivated to the GDP-bound form in a compliant matrix in vitro [83] . It is worth noting that inactivation of Rho is an active process dependent on a compliant ECM, as cells held in suspension in the absence of an ECM matrix, where they are rounded, have high Rho-GTP levels, while cells in a compliant matrix down-regulate Rho-GTP [83] . A role for Rho in vivo is demonstrated by the finding that Rho/ROCK regulation by FAK is necessary for mammary branching morphogenesis [87] . This may be a direct activation of Rho by FAK binding to p190RhoGEF [88] .
Evidence is accumulating for the role of p190RhoGAP-B, which regulates Rho to the inactive state [89] , in regulating Rho in the mammary gland. We find that p190RhoGAP-B down-regulates when MECs are cultured in compliant matrices, and does so by localizing Rho to cell-cell junctions where it is spatially inactivated (Ponik and Keely, in preparation). While it would be straightforward to predict that decreased Rho activation by p190-B should inhibit tumorigenesis, in fact the converse is true: increased p190-B levels enhance tumor formation [90] . Expression of p190RhoGAP-B is highest at the TEBs of the developing mammary gland, and is re-expressed in some mammary tumors [91] . Loss of p190-B results in decreased proliferation of the cap cells in the TEBs, and a resulting decrease in ductal morphogenesis [92] . The paradoxical effect of p190-B is linked to its ability to regulate Rac and IGF signaling pathways [90, 92] . These findings suggest that there is a balance of Rho regulation, and cross-talk with 
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Actin-myosin Contractility Figure 2 Rho-ROCK mediated contractility is a sensor for matrix stiffness. Under conditions of a stiff matrix, contractility cannot overcome the stiffness of the matrix, and it is proposed that this results in isometric tension, the formation of matrix adhesions, activation of FAK, and maintenance of high Rho activation. The result is proliferation and an invasive phenotype, and a disruption of morphogenesis. Under conditions of compliance, contraction results in matrix remodeling, changes in cell shape, down regulation of Rho, down regulation of adhesive signaling events, controlled proliferation, and branching morphogenesis growth factor signaling that is likely to regulate whether the ECM is tumor suppressive or tumor promoting.
FAK as a Mediator of Proliferation and Survival
Activation of focal adhesion kinase (FAK) is one of the dominant integrin-mediated signaling events, and FAK is emerging as a central regulator of mammary phenotype and mammary gland development. Targeted loss of FAK in the mammary epithelial cells results in a gland that is hypoplastic, and corresponds to diminished activation of ERK and expression of cyclin D1, suggesting the defect is due in part to diminished cell proliferation during lobuloaveolar development [93] . Loss of FAK also results in decreased Stat5 phosphorylation and resulting loss of whey acidic protein [93] , consistent with the finding that β1 integrin signaling to Stat5 is important for alveolar differentiation [55] . It is important to point out that FAK is involved in developmental events that are dependent on cell proliferation, supporting a role for an integrin-FAK-ERK pathway in regulating proliferation in response to ECM.
The role for FAK in regulating cell proliferation is further supported by the finding that FAK is strongly implicated in tumor formation. Several independent investigators demonstrated that loss of FAK suppresses tumor formation in mouse models [96] [97] [98] [99] . This is consistent with the finding that FAK is often over-expressed in human breast carcinomas [100] . Analysis of genes regulated by FAK loss in mouse mammary tumors link FAK to proliferation genes involved in both G1 and G2/M [78, 101] . FAK loss results in the down-regulation of several signaling pathways that link to proliferation including ERK, PI3K, and Rho/ROCK [97] [98] [99] .
FAK levels are increased in many breast carcinoma samples [102] , and FAK is associated with increased progression in several tumors including breast [103, 104] colon carcinoma, and astrocytoma [105, 106] . FAK transcriptional expression is increased by the action of NF-kB, which is an important survival mediator [107, 108] . However, the finding that FAK levels diminish in some liver and cervical carcinomas [109, 110] and that FAK phosphorylation does not always correspond to tumor progression and metastasis [111] suggests that extracellular signals impinge upon FAK and determine its role in tumor suppression or progression.
The role of FAK in tumor suppression is likely not direct, but a consequence of controlling FAK activation and localization. In compliant matrices, FAK is not localized to matrix adhesions, but rather found diffuse in the cytoplasm. Under these conditions, cells are able to undergo ductal morphogenesis in vitro [67, 68, 83] . In contrast, within stiff matrices, FAK is phosphorylated and localized to 3D matrix adhesions, where it has enhanced binding to its downstream effectors including Src, SHC, and Grb2 [68] . Consistent with regulation by ECM stiffness, several studies link FAK activation to the contractile action of Rho/ROCK [84, 87, 112] . Therefore, a model can be proposed in which a compliant ECM serves to suppress tumor formation in part by regulating the localization of FAK such that it is not associated in 3D focal adhesions, and cannot activate proliferative signaling pathways.
While FAK is strongly linked to tumor progression and cellular proliferation, FAK knock-out does not inhibit lactogenesis. Rather, the integrin-binding protein, ILK is linked to lactogenic differentiation [94] (Fig. 3) . Moreover, activated Rac rescues an ILK−/− mammary gland, pointing to an signaling axis of ECM-β1 integrin-ILK-Rac-Stat5-lactogenic genes [94] . These results are consistent with the evolving role for Rac in promoting mammary differentiation. The role of ILK, like integrins, is balanced, however, as forced overexpression of ILK disrupts differentiation and promotes a carcinoma phenotype [95] , demonstrating again that signaling pathways involved in differentiation must be appropriately controlled.
Proliferation and pERK
Several investigators have demonstrated that activation of FAK downstream of integrins signals directly to the Ras/ ERK pathway and also regulates growth-factor signaling to this pathway [113] [114] [115] [116] [117] . In the context of matrix stiffness, a dense or stiff matrix activates pERK in mammary epithelial cells, while a compliant matrix does not [67, 68] . A striking feature of cells that are cultured in compliant 3D collagen matrices is that cell proliferation is markedly attenuated in a compliant matrix compared to stiff 3D or 2D matrices, which is linked to the down-regulation of the proliferation signature downstream of pERK activation [68] . Moreover, inhibition of MEK reverts the invasive phenotype, and promotes normal tubulogenesis in a stiff 3D collagen matrix [68] . These findings support the notion that one way a compliant matrix is tumor-suppressive is by controlling activation of the MEK/ERK pathway.
Several growth factor receptors also signal to FAK and pERK, including PDGF, EGF, and HGF, and this may represent a means by which control of FAK and ERK by a compliant ECM can regulate growth factor signaling pathways [117, 118] (for review see [119] ). Although there is not space to consider this cross-regulation here, the case of HGF regulation in mammary cell phenotype is particularly appropriate for the consideration of how ECM stiffness might regulate growth factor signaling. HGF, in combination with TGFβ, regulates mammary gland branching morpho-genesis [120] . Consistent with this finding, when HGF is added to MECs that are within a compliant 3D collagen gel, it converts ascinar structures into branching tubules [121] . In contrast, HGF added to either transformed or normal mammary epithelial cells within a stiff collagen gel instead promotes cell invasion [68] . This demonstrates that matrix stiffness regulates the outcome of HGF signaling to promote tubulogenesis in a compliant matrix and invasion in a stiff matrix. The signaling between the ECM and HGF is likely bi-directional, as HGF enhances integrin-mediated cell adhesion, signaling to FAK and paxillin, and localization of ERK to focal complexes, all of which are required for both migration and ductal morphogenesis [122] [123] [124] [125] .
Negative Cross-Talk Between FAK and p53
The p53 protein is a complex tumor suppressor that promotes apoptosis, but is often mis-regulated in carcinomas through mutation, resulting in mutant p53 forms that gain function and contribute to tumor formation. One of the means by which the ECM inhibits apoptosis is through the inhibition of p53 by FAK [126] . The regulation is direct, as activated FAK localizes to the nucleus and binds directly to p53 to inhibit its function [127, 128] . The N-terminal FERM domain of FAK mediates this function, as this domain binds to p53 and has a nuclear localization sequence [129] . Moreover, the FERM domain of FAK binds Mdm-2 and coordinates ubiquitination of p53 to cause p53 degradation [129] . Under conditions of decreased adhesion, FAK is not activated, and instead links to increased phosphorylation of JNK to regulate p53 and promote apoptosis [130] . FAK is in turn transcriptionally down-regulated by p53 [108, 127] , which could serve to further suppress FAK signaling in compliant matrices. We found that many genes that are regulated by FAK have p53 binding sites in their promoter, further solidifying the link between FAK, p53, and transcriptional regulation [68] . Tumor-suppression/Morphogenesis Mutant p53 promotes cell transformation and invasiveness. Interestingly, one mechanism by which it effects this outcome is through increased recycling of integrin and EGFR, which serves to constitutively activate signaling downstream of EGFR [131] . In MCF10A cells, mutant p53 blocks the apoptosis that results in luminal clearing, and results in expression of several mesenchymal markers [132] . Recent data suggests a mechanism for this result, by linking p53 to regulation of miR-200c, a negative regulator of the mesenchymal phenotype [133, 134] .
Apoptosis and Survival Regulation Due to the ECM
Loss of adhesion to the ECM in cells that are anchoragedependent and express integrins leads to apoptotic cell death, which when induced by loss of adhesion is termed anoikis [135] . Intriguingly, an appropriately polarized epithelium that is adherent via α6β4 integrin to the basal lamina is resistant to apoptosis, but only if the cells exit the cell cycle [136] . While this finding is linked to appropriate adhesion to the basal lamina, there is likely a mechanical component as well, since the effect requires the formation of a polarized ascinar structure in a compliant rBM, and does not occur for adhesion to rigid 2D surfaces coated with collagen or fibronectin [136] .
During lumen formation within compliant 3D cultures with human MCF-10A cells, it was shown that the lumen initially contains cells, and then later the lumen is cleared by apoptosis (Fig. 1) . Lumen formation requires the proapoptotic regulator, Bim, a member of the BCL-2 protein family [137] , and loss of Bim in mice results in a delay in lumen formation and the formation of squamous transdifferentiation in the mammary gland [138] . Apoptosis to form a lumen is proposed to be anoikis due to loss of adhesion to the basement membrane [139] , as adhesion via α6β4 to laminin-5 in polarized epithelial cells ensures cell survival via Rac, PAK-1, and NF-kB inhibition of apoptosis [140] [50] (Fig. 3) . The appropriate formation and maintenance of a lumen is clearly linked to tumor suppression, as luminal filling is a sign of the earliest of mammary carcinomas: Ductal or Lobular Carcinoma in situ (DCIS and LCIS, respectively).
FAK activation protects cells from anoikis [141] , and thus its regulation may be a mechanism controlling lumen formation. Consistent with this, FAK regulates several genes linked to survival including the Bcl-2 family [68] . The regulation of FAK may help explain the loss of luminal formation that is observed when mammary epithelial cells are cultured in stiff vs compliant matrices; in a stiff matrix where FAK activation is increased, cells that detach from the basal lamina could persist and prevent clearing of the lumen. Resistance to anoikis is a property of stem cells, evidenced by their ability to form adhesion-independent mammospheres. Thus, it is exciting to note that loss of FAK leads to a loss of stem/progenitor cells [99] ; it is likely that a further role for FAK in determining stem cell fate will continue to emerge.
In addition to regulation by attachment to the basement membrane, Bim is regulated by EGFR (ErbB1) in vitro [137, 142] , and its down-regulation may account for the luminal filling noted when ErbB2 is stimulated and artificially cross-linked [143] . The complex cross-talk between integrins and EGFR family members has important clinical implications, as expression levels of ErbB2, also known as Her2 or the neu oncogene, are used to predict breast cancer outcome and to determine therapy with antiher2 agents.
Tumor cells can escape anoikis by secreting autocrine laminin-5 [140] (Fig 3) . In addition, tumor cells form aggregates that allow survival by adhesion to fibronectin secreted by neighboring cells [144] . Cells that are adherent to dense collagen evade apoptosis by regulating several apoptotic mediators including Bcl-2 family members (see supplemental material in [68] ). Thus, tumor formation is characterized by evasion of the tumor-suppressive apoptotic pathways.
ECM Regulation of Tumor Suppression via miRNAs
A recent and exciting finding suggests that ECM affects the expression of genes at the mRNA level through the action of miRNAs, and this mechanism needs to be considered in a discussion of how the ECM may act to suppress tumor formation. Because each miRNA has multiple targets, this allows a rapid and global control of several messages at once. miRNAs regulate genes by binding to the untranslated sequences in mRNAs and targeting them for degradation.
The miR-200 family, composed of miR-200a,b, and c isoforms, is emerging as a central regulator of cellular phenotype. The general finding is that miR-200 serves to suppress the mesenchymal phenotype, and promote the epithelial phenotype in several epithelial tissues, including the mammary gland [145] . Targets of miR-200 include the transcription factors Zeb-1 and Zeb-2, and SUZ12, which in turn down-regulate E-cadherin [145] [146] [147] . Thus, the result of miR-200 is to maintain E-cadherin levels and suppress tumorigenesis. Other direct targets of miR-200 are also implicated in the mesenchymal phenotype and include fibronectin, moesin, NTrk2, tubulin β3, and VEGF, all of which are increased in breast carcinomas [148] . Other miRNAs including miR-205, miR-192, and miR-9 target Zeb1 or 2, and regulate E-cadherin levels [133, 149] . Because of the extensive regulation of cell response to the ECM by E-cadherin, whether a particular ECM is tumor suppressive or not may be affected by miRNA regulation of cell phenotype.
The regulation of these miRNAs is not fully understood. The ECM is implicated in regulating miR-200 through the TGFβ-mediated induction of TWIST and Snail, which inhibit miR-200 [147] . If miR-200 is constitutively expressed, TGF-β induced EMT is blocked, pointing to the necessary role of this global regulator [150] . Moreover, it has been noted that miR-200 allows cells to move back and forth between epithelial and mesenchymal states, and surprisingly it is the metastatic cells that retain responsiveness to the morphogenetic control of rBM, leading to the proposal that miR-200 allows cells the phenotypic flexibility to respond to the microenvironment [150] . This idea is consistent with the observation that miR-200 targets molecules important in maintaining stem cell properties [148, [150] [151] [152] [153] [154] , and adds further support to the idea that the ECM regulates stem cell properties.
The levels of miR-200 are positively regulated by p53 [133, 134] and regulated by the balance of Akt1/Akt2 [155] . Thus, a model that can be proposed is that a compliant matrix, which only minimally activates FAK, does not cause the degradation of p53, allowing the expression of miR-200 and the maintenance of the epithelial phenotype. In contrast, a matrix with increased stiffness will activate FAK, which in turn activates PI-3-kinase and Akt, which inhibits miR-200 and will allow a mesenchymal phenotype. Moreover, a stiffer ECM increases expression of TWIST-2 [68] , which also inhibits miR-200 expression and promotes a mesenchymal phenotype [152, 155] .
The micro-RNA molecules participate in a feedback regulation to the ECM, as several miRNAs, including miR-29, miR-200, miR-124, miR-335, and let-7, target ECM proteins, integrins, and/or cadherin (for a complete review, see Valaystan and Weinberg [156] ). Moreover, miR-205 targets FAK, and therefore could dramatically affect the response of cells to the ECM and regulate whether the ECM promotes tumorigenesis or is tumor-suppressive for a particular cell.
Summary: Matrix Stiffness Regulates Whether Integrins Suppress or Promote Tumor Formation
As discussed in this chapter, there are several models to explain how integrins serve to maintain cellular architecture and suppress tumor formation, yet also promote tumor progression. It is clear that while cells are adherent to an intact basal lamina, the collaboration between α6β4 integrin and other β1 integrins serves to regulate signaling pathways and promote cellular polarization. Moreover, the formation of cadherin-based cell-cell adhesions further restricts proliferative signals and maintains tumor suppression. Upon degradation of the basal lamina by several proteases, either during involution or during tumor progression, a switch in the composition of the ECM can activate different integrin isoforms, and will alter the signals that result. Tumor invasion in many ways is a recapitulation of developmental events at the proliferative and invasive TEB, which serves to invade into the mammary fat pad and result in a branched ductal tree. The matrix around the TEB during involution, and around tumors during tumor progression is altered both in matrix composition, and in its orientation, such that aligned stromal fibronectin and collagens accompany ductal morphogenesis, involution, and tumor cell invasion. These changes to the ECM result in matrices that are stiffer, which cells can sense via Rho/ROCK mediated contraction against the matrix. Thus, in a stiffer matrix, integrin signaling is enhanced and mis-regulated. This localizes FAK to 3D matrix adhesions, where it is activated and collaborates with additional signaling pathways including pERK and PI-3-kinase to promote proliferation. Moreover, FAK activation inhibits p53 and miR-200, which regulate epithelial phenotype and apoptosis. Thus, a reasonable hypothesis is that integrin signaling is controlled in a compliant matrix by controlling the level of signaling downstream to FAK in a manner that allows cell survival, controlled proliferation, and appropriate differentiation. Currently much less is known about how the ECM might serve to prevent tumor formation, but as our understanding continues to grow, it will become more feasible to incorporate a consideration of the ECM in prevention, prognosis and treatment of breast cancer.
